Piper Sandler Begins Coverage on Sotera Health (NASDAQ:SHC)

Piper Sandler initiated coverage on shares of Sotera Health (NASDAQ:SHC) in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage issued a neutral rating and a $13.00 price target on the stock.

SHC has been the subject of several other research reports. Barclays dropped their target price on shares of Sotera Health from $19.00 to $14.00 and set an overweight rating for the company in a report on Wednesday, April 10th. Citigroup upgraded Sotera Health from a neutral rating to a buy rating and lowered their target price for the company from $18.00 to $16.00 in a report on Wednesday, April 3rd. Royal Bank of Canada restated an outperform rating and issued a $20.00 price objective on shares of Sotera Health in a report on Monday, March 4th. KeyCorp initiated coverage on shares of Sotera Health in a research report on Tuesday, February 6th. They issued a sector weight rating for the company. Finally, TheStreet raised Sotera Health from a d rating to a c- rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sotera Health currently has an average rating of Moderate Buy and an average price target of $16.92.

Sotera Health Stock Up 0.1 %

SHC stock opened at $11.20 on Tuesday. Sotera Health has a one year low of $10.71 and a one year high of $19.40. The firm has a market cap of $3.17 billion, a PE ratio of 58.95 and a beta of 2.08. The firm’s 50 day moving average price is $11.43 and its 200-day moving average price is $13.82. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.86 and a current ratio of 3.20.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). Sotera Health had a return on equity of 48.47% and a net margin of 5.09%. The business had revenue of $248.18 million for the quarter, compared to analysts’ expectations of $254.73 million. On average, equities research analysts anticipate that Sotera Health will post 0.63 EPS for the current year.

Insiders Place Their Bets

In other news, Director Pincus & Co. Warburg sold 16,594,363 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.31, for a total value of $237,465,334.53. Following the completion of the sale, the director now directly owns 88,822,952 shares of the company’s stock, valued at approximately $1,271,056,443.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sotera Health news, Director Pincus & Co. Warburg sold 16,594,363 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the transaction, the director now directly owns 88,822,952 shares of the company’s stock, valued at approximately $1,271,056,443.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael P. Rutz sold 83,109 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $1,189,289.79. Following the completion of the sale, the insider now directly owns 544,409 shares of the company’s stock, valued at $7,790,492.79. The disclosure for this sale can be found here. Corporate insiders own 55.12% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Tudor Investment Corp Et Al grew its position in Sotera Health by 27.4% in the 3rd quarter. Tudor Investment Corp Et Al now owns 350,487 shares of the company’s stock valued at $5,250,000 after buying an additional 75,487 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Sotera Health by 3.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 881,919 shares of the company’s stock worth $13,211,000 after purchasing an additional 30,197 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in shares of Sotera Health during the 3rd quarter worth approximately $58,000. Untitled Investments LP boosted its stake in shares of Sotera Health by 39.9% in the third quarter. Untitled Investments LP now owns 958,595 shares of the company’s stock valued at $14,360,000 after buying an additional 273,520 shares in the last quarter. Finally, Element Capital Management LLC purchased a new stake in shares of Sotera Health in the third quarter valued at approximately $1,119,000. Institutional investors and hedge funds own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.